People with Down syndrome are living longer than ever, a testament to medical progress and increased public awareness. However, greater longevity also brings new health challenges. That’s why EU-funded research programs like GO-DS21 and ICOD are so important. As highlighted in a recent Horizon Magazine article, these initiatives are making significant strides in reducing the long-term health impacts of Down syndrome and improving lifelong well-being.
The article highlights how these EU-backed projects are delivering real change—from developing better tools to understand the links between Down syndrome and other health conditions like obesity, diabetes, intellectual disability, and dementia, to advancing promising treatments. One exciting area of progress is the development of a potential drug treatment to address cognitive impairment in individuals with Down syndrome.
Key takeaways from the research include:
- Reducing health risks associated with Down syndrome
- Improving long-term quality of life
- Expanding treatment options
At EDSA, we proudly support these research programs. We’re inspired by the progress and are committed to ensuring that scientific breakthroughs lead to real-world benefits for people with Down syndrome across Europe. We believe this marks the beginning of a new era in inclusive, compassionate healthcare.
👉 Read the full article here.
